Abiraterone acetate versus bicalutamide in combination with gonadotropin releasing hormone antagonist therapy for high risk metastatic hormone sensitive prostate cancer

Abiraterone acetate versus bicalutamide in combination with gonadotropin releasing hormone antagonist therapy for high risk metastatic hormone sensitive prostate cancer

Abstract The objective of this study was to compare the efficacy of abiraterone acetate with that of bicalutamide in combination with gonadotropin-releasing hormone (GnRH) antagonist treatment for patients with high-risk metastatic hormone-sensitive prostate cancer (mHSPC). A total of 149 patients w...

Full description

Bibliographic Details
Main Authors: Takashi Ueda, Takumi Shiraishi, Saya Ito, Munehiro Ohashi, Toru Matsugasumi, Yasuhiro Yamada, Atsuko Fujihara, Fumiya Hongo, Koji Okihara, Osamu Ukimura
Format: Article
Language:English
Published: Nature Publishing Group 2021-05-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-021-89609-2

Internet

https://doi.org/10.1038/s41598-021-89609-2

Similar Items